Join

or

Existing user? Login

Adverse drug events

Inhaled corticosteroids in COPD have neutral effect on mortality despite increased pneumonia risk

Use of inhaled corticosteroids in patients with chronic obstructive pulmonary disease (COPD) is associated with an increased risk of pneumonia. In the image, close up of a man using oxygen nasal tubes

Source: incamerastock / Alamy

Researchers undertook a meta-analysis of 38 studies of patients with chronic obstructive pulmonary disease (COPD) who used inhaled corticosteroids

The use of inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) is associated with an increased risk of pneumonia but a neutral or even reduced risk of pneumonia-associated and overall mortality, results of a meta-analysis indicate.

Previous studies have suggested that ICS have immunosuppressant and potent anti-inflammatory effects, which the researchers say may explain their overall impact on mortality in patients with COPD.

“Although ICS might predispose COPD patients to the increased risk of pneumonia, their anti-inflammatory and/or other mitigating effect might paradoxically counterbalance this risk and result in similar or possibly improved mortality,” says Ena Gupta, the study’s lead author, from University of Florida College of Medicine.

The research was presented at the 2015 American Thoracic Society International Conference[1], held in Denver, Colorado.

Gupta’s group performed a literature review of randomised controlled trials and observational studies of patients with COPD using ICS, published since the late 1990s.

Their meta-analysis, which included 38 relevant studies, found that the unadjusted risk of pneumonia was increased in patients using ICS, with relative risks (RR) ranging from 1.61 in randomised controlled trials (95% confidence interval [CI] 1.35-1.93) to 1.89 in observational studies (95% CI 1.39-2.59).

By contrast, overall and pneumonia-associated mortality were apparently unaffected or reduced by ICS use: RRs ranged from 0.79 (95% CI 0.65-0.97) to 0.95 (95% CI 0.85-1.05) for overall mortality, and from 0.72 (95% CI 0.59-0.88) to 0.91 (95% CI 0.52-1.59) for pneumonia-associated mortality. However, there was significant heterogeneity among studies, the researchers note.

Citation: Jizak DOI: 10.1211/PJ.2015.20068595

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Jizak, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Supplementary images

  • Use of inhaled corticosteroids in patients with chronic obstructive pulmonary disease (COPD) is associated with an increased risk of pneumonia. In the image, close up of a man using oxygen nasal tubes

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.